Infectious Disease Point of Care Diagnostics Market to Rise at 17.4% CAGR and Reach $3371.1 Million by 2027; Increasing Investments in Product R&D will Bode well for Market Growth, says Fortune Business Insights™

    NEXT STORY
    Allied Corp. Strengthens National Brand Support with the Signing of Elite Athlete Camille Leblanc-Bazinet
    PREV STORY
    Allarity Therapeutics Publishes Interim Report for the Period January – September 2020
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    TESARO Announces Updates to the U.S. Prescribing Information for VARUBI® (rolapitant) Injectable Emulsion

    WALTHAM, Mass., Jan. 12, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical ...

    author_avatar
    NASDAQ Market News

     Replimune Presents Initial Clinical Data with RP1 that Strongly Supports Expansion of Clinical Programs in Melanoma and Cutaneous Squamous Cell Carcinoma (CSCC)

    author_avatar
    NASDAQ Market News

    TESARO, Inc. Gives Notice of Anticipated Make-Whole Adjustment Event to Holders of Its Convertible Senior Notes

    WALTHAM, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical ...

    author_avatar
    NASDAQ Market News